Institute of Cancer
-
Upload
filipa-rosa -
Category
Documents
-
view
215 -
download
0
Transcript of Institute of Cancer
-
7/31/2019 Institute of Cancer
1/30
POSTGRADUATEPROSPECTUSTHE INST ITU TE O F C ANC ER R ESEAR CH, LO NDON
-
7/31/2019 Institute of Cancer
2/30
ContentsWelcome rom Academic Dean - Proessor Alan Horwich 3
Vision and Mission 4
10 Reasons to Choose the ICR 5
Meet the Student President 8
Meet our Alumni 9
ICR Research Sections:
Chelsea Site
The Breakthrough Toby Robins Breast Cancer Research Centre 11
Gene Function and Regulation 12
Structural Biology 12Cell and Molecular Biology (including the Cancer Research UK Tumour Cell Signalling Unit) 13
Sutton Site
Cancer Therapeutics (including the Cancer Research UK Cancer Therapeutics Unit) 14
Cancer Research UK/EPSRC Imaging Centre 15
Epidemiology 15
Joint Department o Physics 16
Academic Radiotherapy and Department o Radiotherapy (including the Psychology Research Group) 17
Clinical Trials 17
Cancer Genetics 18
Paediatric Oncology 18
Haemato-oncology 19
Medicine 20
Molecular Carcinogenesis 21
Our Campus 22
Student Support and Resources 23
e-Learning Resources 24
Library and Inormation Services 25
The Registry 26
Learning and Development 26
Our Commitment to Equality and Diversity 28
Condentiality and Data Protection 28
How to Apply 29
Senior Ocers and Academic Deans Team 30
-
7/31/2019 Institute of Cancer
3/30
Welcome rom Academic DeanThe Institute o Cancer Research is at the oreront o science in the ght
against cancer and we are proud o our international reputation. This
prospectus is designed to give you a avour o lie here by introducing our
wide variety o research activities and it advises on the next steps i you want to
develop your career with us in this dynamic environment.
Cancer research itsel in all its many aspects ofers unparalleled challenges,
intellectually and practically, in a very wide range o subjects, including physics
and chemistry as well as cell and molecular biology. The ICR is ortunate in
its close partnership withThe Royal Marsden NHS Foundation Trust, which
acilitates translational research.
Our Scientic Strategy is based around exploiting knowledge o cancer genes or patient benet, achieved
through development o therapeutic technologies, discovery o better tools or diagnosis and clinicalmonitoring, and analysis o how genetic background may predispose to cancer and inuence response to
therapy.
The ICR has made many important contributions to cancer research through its ocus on a combination
o genetics, molecular biology, drug discovery and development, and cancer diagnosis and treatment.
The quality o our research was armed by the Higher Education Funding Councils Research Assessment
Exercise in 2008. The Times Higher Education analysis o these results ranked us rst amongst all UK
universities entering more than one subject area o assessment, with 37% o our research scoring 4 star
(world-leading) and a urther 42% scoring 3 star (internationally excellent).
As well as high standards o research, we seek to provide high quality training or all our graduate students.We have a programme o academic activities designed to complement the day-to-day research laboratory
experience o science. We want your time with us to be ruitul, productive and enjoyable and we aim to
equip you with a range o outstanding skills as a springboard or your uture career. We are proud that
our graduateshave gone on to make signicant discoveries in the eld o cancer research and treatment,
thereby improving and enriching the lives o many people.
Thank you or the interest you have shown in our work and good luck in your research career.
Proessor Alan Horwich
POSTGRADUATE PROSPECTUS PAGE 3
http://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/about_us/scientific_strategy/index.shtmlhttp://www.icr.ac.uk/education/clinical_trainee_opportunities/meet_alumni/index.shtmlhttp://www.icr.ac.uk/education/clinical_trainee_opportunities/meet_alumni/index.shtmlhttp://www.icr.ac.uk/education/clinical_trainee_opportunities/meet_alumni/index.shtmlhttp://www.icr.ac.uk/about_us/scientific_strategy/index.shtmlhttp://www.royalmarsden.nhs.uk/home -
7/31/2019 Institute of Cancer
4/30
Vision and Mission
Our VisionIs that people may live their lives ree rom the ear o cancer as a lie threatening disease
Our MissionIs to relieve human sufering by pursuing excellence in the ght against cancer through:
Research into the causes, prevention, diagnosis and methods of treatment of cancer
Education and advanced training of medical and scientic sta
Treatment and care of the highest quality for cancer patients
Attraction and development of resources to the optimum eect
POSTGRADUATE PROSPECTUS PAGE 4
-
7/31/2019 Institute of Cancer
5/30
10 Reasons to Choose the ICR
1 Excellent Financial SupportPhD studentships unded by the ICR, Cancer Research UK, MRC or EPSRC are supported or our years.
The 2011/12 non-taxable stipend will be 19,500 (inner London - Chelsea) or 18,180 (outer
London Sutton). A number o Wellcome Trust studentships with higher stipends are also available.
2 University o London Degree and BenetsWe are a College o the University o Londonand as such our students graduate rom a globally
recognised world leader in higher education. All our students have ull access toThe University o
London Union (ULU)sports clubs, societies and acilities including gym, swimming pool, caes, bars
and music venues.
3 Support rom World-ClassResearchersAll our students receive advanced scientic
training at the cutting edge o cancer research
guided by a aculty o world-class researchers.
To date, all o our PhD submissions have been
successul. In 2007 we were third highest in the
Higher Education Funding Council or Englands
report on Research Degree Qualication Rates,
and our qualication rates remain high.
4 Proven Scientic ExcellenceOur record o achievement in understanding
the genetic epidemiology and molecular
pathology o cancer and our work in the area o
therapeutic development is second-to-none.
We are the most efective University in
the UK in terms o the impact on our scientic
peers o our published work in biomedical
sciences (Source: Evidence Ltd). The qualityo our research was armed by the Times Higher
Educations interpretation o the 2008 Research
Assessment Exercise, which ranked the ICR as
the UKs top academic research centre.
POSTGRADUATE PROSPECTUS PAGE 5
http://www.lon.ac.uk/http://www.ulu.co.uk/http://www.ulu.co.uk/http://www.ulu.co.uk/http://www.ulu.co.uk/http://www.lon.ac.uk/ -
7/31/2019 Institute of Cancer
6/30
5 Cutting-edge Scientic FacilitiesMore than 90% o the ICRs laboratory estate has been built anew or reurbished over the last 10
years, ensuring that we have modern and ecient laboratories. The ICR has just completed a ve-
year programme during which we invested over 8 million in new scientic initiatives involving the
recruitment o additional world-class researchers to our aculty and the purchase o state-o-the-art
equipment.
6 Ability to Conduct Translational ResearchClose collaboration between our Research Sectionsand our partnership withThe Royal Marsden
enhances our ability to translate research ndings into patient benet. In the last 10 years, the ICR
has taken 10 cancer drugs into clinical trials, an achievement unmatched anywhere in the world.
7 On-site Sport and Social FacilitiesOur Student Committeeorganises a range o on-site sporting and social activities to connect
students across both our sites:
ChelseaOur central-London location provides easy access to a huge variety o caes, bars and restaurants as well
as countless historical and modern attractions. We run a number o sports clubs on a regular basis, such
as a highly successul cricket team.
SuttonWe ofer a range o on-site sporting acilities including a swimming pool, gym, and tennis and squash
courts. Sports clubs include yoga, karate, circuit training and ultimate Frisbee. During the summer, we
hold a Mini-Olympics, which sees mixed teams competing against each other in a variety o sportsincluding swimming, squash, table tennis and video games! Traditionally, our students organise a
barbeque to celebrate the sporting event at the Finals Night.
pH BarThe pH bar, located at our Sutton site, is open every Thursday and Friday and has cheap drinks, pool and
snooker tables, dart board and table ootball. All ICR staf have access to the bar, which is run entirely by
student and staf volunteers.
POSTGRADUATE PROSPECTUS PAGE 6
http://www.icr.ac.uk/research/research_sections/index.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/education/education_strategy/student_committee/index.shtmlhttp://www.icr.ac.uk/education/education_strategy/student_committee/index.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_sections/index.shtml -
7/31/2019 Institute of Cancer
7/30
The diversity o our students enriches academic andsocial lie at the ICR; we have students rom all over the
world. China, Greece, India, Israel, Korea and Spain are justa ew o the countries represented.
8 Access to Tailored ResourcesWe have award-winning resources or PhD students written by our Interactive Education Unit:
Perspectives in Oncology - the cancer science website and a Study Skills website.
9 Comprehensive Learning and DevelopmentWe provide a wide range o orums and activities to support the personal and proessional
development o our students. These include research group seminars, the ICRs AnnualConerence, an extensive guest seminar programme and a Science Communication Course.
Students are also encouraged and supported to attend and present at national and international
conerences, such as AACR. We provide all our students with 10 days personal development
per annum.
10 More than an EducationThe diversity o our students enriches academic
and social lie at the ICR; we have students rom
all over the world. China, Greece, India, Israel,
Korea and Spain are just a ew o the
countries represented. We not only provideour students with irst-class scientiic
training but also the opportunity to make
lie-long riends and meet potential
scientiic collaborators.
POSTGRADUATE PROSPECTUS PAGE 7
-
7/31/2019 Institute of Cancer
8/30
Meet The Student President
Jamie MallinsonJamie began his PhD entitled Functionalised Macrocycles as Scafolds orthe Discovery o Novel Protein Kinase Inhibitors at the ICR in 2009 under thesupervision oDr Ian Collins in theCancer Research UK Cancer TherapeuticsUnit. In January 2010, Jamie was voted Student President o the ICR StudentCommittee; he is also a student representative on the Ups Club committee.
Ater spending time in industry labs as an undergraduate, Jamies
comparative impression o the acilities and research at the ICR helped
make his decision to apply or his PhD. The labs at the ICR are o the
highest standard, and are comparable to those ound in industry. They
are very well equipped and have the latest technologies he explains.
Jamie was impressed by the scope o research being undertaken at the ICR: I think being exposedto both academic research and drug discovery at the ICR really prepares you or the uture.
Along with his challenging PhD project, Jamie has taken on the responsibilities o Student
President where he makes sure that the student opinion is listened to. Since being voted into the
role by other students in the annual elections, he has organised and chaired various meetings or
the Student Committee the student run organisation which mediates communication between
students and the ICR.
The Student Committee represents all students at the ICR, and is involved in decision making at all
levels, Jamie explains. The Committee is always involved in major decisions that aect students.
For example, we were involved in the discussions and debates about the introduction o plagiarismdetection sotware.
There is regular eedback between the StudentCommittee and the ICR in order to continually improvethe standard o our education.As well as helping students to have their say on academic matters, Jamie helps coordinate the
sports and social activities available at the ICRs Ups Club, including the Mini-Olympics Finals night
party: There are many students rom varied backgrounds, and all are really r iendly. We have loads
o great scientiic discussions, but also a lot o un socially.
POSTGRADUATE PROSPECTUS PAGE 8
http://www.icr.ac.uk/research/research_profiles/4506.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/4506.shtml -
7/31/2019 Institute of Cancer
9/30
Meet Our Alumni
Dr Katy EverettKaty graduated rom the ICR in 2009 with a PhD gained under thesupervision oDr Matilda Katan in the Section o Cell and MolecularBiology. She currently works within the Department o Pharmacologyat the University o Cambridge as a Postdoctoral Research Associate,specialising in cross-talk between calcium and cyclic AMP signallingpathways.
Katys application to the ICR ollowed an interest in her PhD title, Molecular
Mechanisms o Regulation in Phospholipase C gamma enzymes, and Dr Matilda
Katansresearch in the Lipid Signalling Team. She was urther attracted by the ICRs
research reputation, acilities and the city setting o the Chelsea site.
Katy ound her project, which was investigating mutations o the Phospholipase C gamma enzymes (PLC
gamma), both challenging and stimulating: The PLC gamma enzymes, PLC gamma 1 and PLC gamma 2,
are activated downstream o receptor and non-receptor tyrosine kinases. PLC gamma 1 has a role in cell
motility and may act as a common rate limiting step in cancer cell motility downstream rom activated
growth actors and integrins. PLC gamma 2 expression is highest in blood cells and disrupting normal PLC
gamma 2 unction in mice results in a phenotype with similarities to human immune diseases. Although
the pathways that activate PLC gamma isoorms have been well studied, the molecular mechanisms
involved in their regulation through auto-inhibition and activation are not well dened. We introduced a
variety o mutations to PLC gamma 1 and PLC gamma 2 domains to investigate the mechanisms involved
in regulation. Observations supported the idea that the catalytic domain, and a group o domains known
as the specic array, are essential or regulation o PLC gamma activity. The mutants we described mayprove to be useul tools or studying signalling networks involving PLC gamma isoorms.
Throughout her PhD, Katy was supported by both her supervisor and the other enthusiastic
researchers in her lab: Dr Katan made time to discuss students projects with them and was
particularly helpul in giving eedback when it was time to write up.
I would recommend the ICR as a supportive andwell-unded place to do a PhD.Outside o her project, Katy enjoyed the social activities on oer to students, and was a member o
the student committee or two years and a student representative on the Academic Board.
Following her time at the ICR, Katy has ound that the research she carried out has been invaluable
in developing her career: During my PhD I was able to contribute to various papers, which really
opened up more options when applying or postdoctoral jobs.
POSTGRADUATE PROSPECTUS PAGE 9
http://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtml -
7/31/2019 Institute of Cancer
10/30
Dr Matthew GoldMatthew graduated rom the ICR with a PhD in 2007 under the supervision oProessor David Barord in the Section o Structural Biology. He is now on anoverseas research adventure in Seattle as a Sir Henry Wellcome Postdoctoral
Research Fellow. He specialises in the regulation o signalling by scafoldproteins.
Matthew became interested in structural biology during his time as an
undergraduate at Cambridge. In his nal year, he searched or the best
structural biology lab in the UK in which to pursue this interest. My
undergraduate research project advisor recommended the Structural Biology department at the ICR. I
was attracted by my supervisors research, the PhD topic and the unique acilities. Plus, I was impressed
by the antastic quality o research taking place within the other ICR sections.
Ater a successul application, Matthew went on to investigate a class o signal-organising proteins
called A-Kinase Anchoring Proteins (AKAPs): AKAPs direct the action o protein kinase A (PKA),which is a critical regulator o many biological processes, including cell growth, heart rate and
memory ormation.
In the course o my research, I solved the three-dimensional structure o the key PKA-AKAP interace,
which establishes the molecular basis or PKA anchoring. I also determined another crystal structure,
which revealed that one AKAP (AKAP18) can bind to the small molecule AMP this was an unexpected
clue to its unction.
Matthew ound his supervisor to be supportive, encouraging and knowledgeable: David was brilliant
at answering my questions, he allowed me reedom to explore my ideas, and his dedication and
enthusiasm or science set an excellent example. I used some o my unding to pay or a distance-
learning qualiication in Protein Crystallography, to also attend conerences and to oster overseascollaborations.
One o my lasting memories as an ICR graduate student isstumbling out o the synchrotron acility in Grenoble in theearly hours o the morning in pitch darkness under heavysnowall we solved the AKAP18 crystal structure on thattrip!
POSTGRADUATE PROSPECTUS PAGE 10
http://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtml -
7/31/2019 Institute of Cancer
11/30
Our Research SectionsThe Breakthrough Toby Robins Breast Cancer ResearchCentre
Director: Proessor Alan Ashworth FRSThe Breakthrough Breast Cancer Research Centre supports a programme
o cutting-edge biological research to tackle breast cancer, to discover
the causes o the disease, nd methods o prevention, and develop new
treatments and more efective methods or diagnosis. The Centre has very
good interactions with those involved in breast cancer patient care in
The Royal Marsden. The Centre has signicant core acilities and a very active
programme o seminars and meetings.
Apoptosis Proessor Pascal Meier
Cancer Inormatics Dr Marketa Zvelebil
Drug Target Discovery Dr Spiros Linardopoulos
Gene Function Proessor Alan Ashworth FRS
Mammary Stem Cells Dr Matthew Smalley
Molecular Cell Biology Proessor Clare Isacke
Molecular Pathology Dr Jorge Reis-Filho
Endocrinology Proessor Mitch Dowsett
The Breakthrough Breast Cancer Research Centre at theICR supports a programme o cutting-edge biologicalresearch to tackle breast cancer, to discover the causes othe disease, nd methods o prevention, and develop newtreatments and more efective methods or diagnosis.
POSTGRADUATE PROSPECTUS PAGE 11
http://www.icr.ac.uk/research/research_sections/breakthrough/index.shtmlhttp://www.icr.ac.uk/research/research_sections/breakthrough/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/apoptosis/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3930.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/cancer_informatics/index.htmlhttp://www.icr.ac.uk/research/research_profiles/7218.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/drug_target_discovery/index.htmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/gene_function/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/mammary_stem_cells/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4188.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_cell_biology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3469.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_pathology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4190.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/endocrinology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/2737.shtmlhttp://www.icr.ac.uk/research/research_profiles/2737.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/endocrinology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4190.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_pathology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3469.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_cell_biology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4188.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/mammary_stem_cells/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/gene_function/index.htmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/drug_target_discovery/index.htmlhttp://www.icr.ac.uk/research/research_profiles/7218.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/cancer_informatics/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3930.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/apoptosis/index.htmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.icr.ac.uk/research/research_sections/breakthrough/index.shtmlhttp://www.icr.ac.uk/research/research_sections/breakthrough/index.shtml -
7/31/2019 Institute of Cancer
12/30
Section o Gene Function & RegulationChairman: Proessor Peter Rigby FRS
The overall strategy o the Section o Gene Function and Regulation is
to pursue basic research into normal developmental and diferentiation
processes and gain insight into the underlying mechanisms at the levelo gene expression and also chromatin structure. This research is the
prerogative o basic biological science and, since many o the genes that
are disrupted or dysregulated in cancer are regulators o developmental
and diferentiation processes, this programme o work is likely to provide
signicant insight into cancer mechanisms. The Section particularly ocuses
on pathways, systems or processes with obvious cancer relevance.
Molecular Embryology Proessor Peter Rigby FRS
Sexual Development Dr Amanda Swain
Section o Structural BiologyJoint Chairmen: Proessor David Barord FRS& Proessor Dale Wigley FRSResearch teams in the Section o Structural Biology apply techniques o
X-ray crystallography, electron microscopy, biophysics, biochemistry and
molecular biology to understand the structural basis or the unction and
regulation o proteins and complexes implicated in cancer. Our programmes
cover a range o key molecular systems and processes, including signal
transduction, cell-cycle control, transcriptional regulation, targeted protein
destruction,chaperone unction, DNA repair, chromatin modication and
chromosome dynamics. In addition to our basic science programmes, we maintain close links with groups in
the ICR and beyond, in order to develop new therapeutics targeted at these systems using structure-based
drug design.
Barord Group Proessor David Barord FRS
Wigley Group Proessor Dale Wigley FRS
Chromatin Regulation Dr Jon WilsonMitotic Regulation & Cancer Dr Richard Bayliss
Structural Electron Microscopy Dr Ed Morris
Structure-based Drug Design Dr Robert van Montort
POSTGRADUATE PROSPECTUS PAGE 12
http://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/molecular_embryology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/sexual_devlopment/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2874.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/barford_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/chromatin_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/8109.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/mitotic_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/3747.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structural_electron_microscopy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2961.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structure_based_drug_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structure_based_drug_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2961.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structural_electron_microscopy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/3747.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/mitotic_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/8109.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/chromatin_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/barford_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2874.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/sexual_devlopment/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/molecular_embryology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/index.shtml -
7/31/2019 Institute of Cancer
13/30
Section o Cell & Molecular Biology (including the CancerResearch UK Tumour Cell Signalling Unit)Chairman: Proessor Chris Marshall FRSDeputy Chairman: Proessor Richard Marais
The Section o Cell and Molecular Biology encompasses a wide range
o activities, rom studies o gene therapy o cancer to studies on the
mechanism o protein olding. This range o activities reects the underlying
approach o studying basic molecular and cell biology to underpin the
identication o new strategies or cancer therapeutics. A signicant element
o the work in the Section is unded through the Cancer Research UK Programme on Tumour Cell
Signalling Networks. Much o the research in the Section ocuses on the molecular dissection o cancer
genes and how this afects cell signalling. A new initiative within the Section is systems biology, where we
exploit computational biology and network based analysis to understand signalling in tumours.
Antioncogene Proessor Sybille Mittnacht
Cell Communication Dr Claus Jorgensen
Cellular & Molecular Logic Dr Rune Linding
Dynamical Cell Systems Dr Chris Bakal
Hypoxia & Metastasis Dr Janine Erler
Lipid Signalling Dr Matilda Katan
Oncogene Team Proessor Chris Marshall FRS
Protein Folding & Assembly Proessor Keith WillisonProtein Networks Dr Paul Huang
Signal Transduction Proessor Richard Marais
Targeted Therapy Dr Kevin Harrington
The Section o Cell and Molecular Biology encompassesa wide range o activities, rom studies on gene therapy o
cancer to studies on the mechanism o protein olding.
POSTGRADUATE PROSPECTUS PAGE 13
http://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/antioncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2840.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/cell_communication_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14826.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/network_syst_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7882.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/dynamical_cell_systems/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14201.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/hypoxia_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7901.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/oncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_folding%20_and%20_assembly/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2854.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_networks/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/12273.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/signal_transduction/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/targeted_therapy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2858.shtmlhttp://www.icr.ac.uk/research/research_profiles/2858.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/targeted_therapy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/signal_transduction/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/12273.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_networks/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2854.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_folding%20_and%20_assembly/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/oncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7901.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/hypoxia_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14201.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/dynamical_cell_systems/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7882.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/network_syst_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14826.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/cell_communication_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2840.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/antioncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtml -
7/31/2019 Institute of Cancer
14/30
Cancer Research UK Cancer Therapeutics Unit
Section Chairman& Centre Director: Proessor Paul Workman
Deputy Chairman/Director& Head o Chemistry: Proessor Julian Blagg
The Cancer Research UK Cancer Therapeutics Unit is a unique academic drug
discovery group. Its mission is to discover novel and efective small molecule
therapeutics or the treatment o cancer.
Primary aims include:
To identify and validate novel genes and pathways as targets for therapeutic intervention in cancer
To implement innovative technologies for drug discovery
By these means, to discover novel mechanism-based preclinical drug candidates and to progress
these as rapidly as possible rom the laboratory through to hypothesis-testing early clinical trials As a result, to contribute to the improved treatment of human cancers
Cell Cycle Control Dr Michelle Garrett
Clinical Pharmacology & Trials Proessor Ian Judson & Dr Udai Banerji
Computational Biology & Chemogenomics Dr Bissan Al-Lazikani
Gene & Oncogene Targeting Proessor Caroline Springer
Medicinal Chemistry Team One Proessor Julian Blagg
Medicinal Chemistry Team Two Dr Ian CollinsMedicinal Chemistry Team Three Proessor Keith Jones
Medicinal Chemistry Team Four Dr Swen Hoelder
Signal Transduction & Molecular Pharmacology Proessor Paul Workman
Hit Discovery & Structural Design Dr Rob van Montort
Target Discovery & Apoptosis Dr Spiros Linardopoulos
Tumour Biology & Metastasis Dr Suzanne Eccles
POSTGRADUATE PROSPECTUS PAGE 14
http://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/cell_cycle_control/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2774.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/clinical_pharmacology_and_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/comp_bio_chemogen/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/10480.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/gene_and_oncogene_targeting/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2799.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry1/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry2/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/4506.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry3/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2797.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry4/6585.shtmlhttp://www.icr.ac.uk/research/research_profiles/7880.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/signal_transduction_and_molecular_pharmacology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/hit_discovery_structural_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/target_discovery_and_apoptosis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/tumour_biology_and_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2800.shtmlhttp://www.icr.ac.uk/research/research_profiles/2800.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/tumour_biology_and_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/target_discovery_and_apoptosis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/hit_discovery_structural_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/signal_transduction_and_molecular_pharmacology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7880.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry4/6585.shtmlhttp://www.icr.ac.uk/research/research_profiles/2797.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry3/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/4506.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry2/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry1/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2799.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/gene_and_oncogene_targeting/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/10480.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/comp_bio_chemogen/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/clinical_pharmacology_and_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2774.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/cell_cycle_control/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtml -
7/31/2019 Institute of Cancer
15/30
Cancer Research UK/Engineering & Physical SciencesResearch Council (EPSRC) Imaging CentreJoint Chairmen: Proessors Martin Leach& Nandita deSouzaFacilities in the Cancer Research UK/EPSRC Cancer Imaging Centre are
primarily ocused on Clinical Magnetic Resonance (MR), and include: two
clinical 1.5-T MR scanners, a 3T clinical scanner, together with 7-T and
11.7-T experimental systems, and a urther 11.7T system being installed.
The primary research ocus has been on dening the role o MR in cancer
diagnosis, staging, and response assessment.
Other unctional methods are being developed, including preclinical
Positron Emission Tomography-Computed Tomography (PET-CT)
(equipment currently being commissioned) and experimental optoacoustic
imaging. These techniques are being evaluated in a multimodality
approach as prognostic and therapeutic biomarkers, particularly or
determining the action o and response to novel therapeutic agents. All
approaches are increasingly using quantitative methodologies. The Section
is also developing and assessing novel imaging methods or radiotherapy
planning, developing improved analysis or breast cancer, and exploring
basic technologies such as dynamic nuclear polarisation. The Section has
provided analysis methods to academic centres and industry, and has reported methods in cancer.
Imaging Proessors Martin Leach/
Nandita deSouza
Section o Epidemiology
Chairman: Proessor Anthony Swerdlow
The Section o Epidemiology is involved in studies o the aetiology o cancer,
cancer genetics and occupational epidemiology. There is a particular ocus
on breast cancer, but also substantial work on several other cancers including
brain tumours, leukaemia, cervical cancer and mesothelioma. Several large
cohort studies are being undertaken, including the Breakthrough Generations
Study in collaboration with the Breakthrough Breast Cancer Research Centre.Our genetic studies are carried out in collaboration with the Section o
Cancer Geneticsand the Academic Department o Biochemistry. Several o our studies are conducted in
collaboration with the London School o Hygiene and Tropical Medicine.
Aetiological Epidemiology Proessor Anthony Swerdlow
Molecular Epidemiology Proessor Monste Garcia-Closas
POSTGRADUATE PROSPECTUS PAGE 15
http://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/biochemistry/index.shtmlhttp://www.lshtm.ac.uk/http://www.icr.ac.uk/research/research_sections/epidemiology/epidemiology_teams/aetiological_epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/epidemiology_teams/aetiological_epidemiology/index.shtmlhttp://www.lshtm.ac.uk/http://www.icr.ac.uk/research/research_sections/biochemistry/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtml -
7/31/2019 Institute of Cancer
16/30
Joint Department o PhysicsSection Chairman: Proessor Steve Webb
The mission o the Joint Department o Physics, which spans bothThe Royal
Marsden and the ICR, is to develop and apply techniques or cancer diagnosis
and treatment. Within The Royal Marsden, the major roles o the Departmentare to provide support or the clinical activities o radiotherapy, nuclear
medicine and radiology and to manage a radiation protection service.
Within the ICR, the Section pursues a research and postgraduate teaching
programme. Major research areas include: conormal, intensity-modulated
radiation therapy, image-guided radiotherapy, radiopharmaceutical
development, biologically targeted radionuclide therapy, high-ocused ultrasound therapy, ultrasound
and X-ray imaging, detector development and diagnostic imaging. The Department conducts research
into physics as applied to medicine and then acts as the translator o this research into clinical practice.
Clinical Radiotherapy Physics (Fulham) Miss Margaret Bidmead
Clinical Radiotherapy Physics (Sutton) Mr Jim Warrington
Radioisotope Physics Dr Glenn Flux
Radiological Physics Mr Jim Thurston
Radiotherapy Physics Proessor Steve Webb/Dr Phil Evans/
Dr Mike Partridge
Multimodal Molecular Imaging Dr Dimitra Darambara
Therapeutic Ultrasound Dr Gail ter Haar
Ultrasound & Optical Imaging Dr Jefrey Bamber
The mission o the Joint Department o Physics, whichspans both The Royal Marsden and the ICR, is to developand apply techniques or cancer diagnosis and treatment.
POSTGRADUATE PROSPECTUS PAGE 16
http://www.icr.ac.uk/research/research_sections/physics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_fulham/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_fulham/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_sutton/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_sutton/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radioisotope_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiological_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiotherapy_physics_research_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.icr.ac.uk/research/research_profiles/4591.shtmlhttp://www.icr.ac.uk/research/research_profiles/7750.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/therapeutic_ultrasound_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2938.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/ultrasound_and_optical_imaging_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2939.shtmlhttp://www.icr.ac.uk/research/research_profiles/2939.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/ultrasound_and_optical_imaging_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2938.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/therapeutic_ultrasound_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7750.shtmlhttp://www.icr.ac.uk/research/research_profiles/4591.shtmlhttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiotherapy_physics_research_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiological_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radioisotope_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_sutton/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_fulham/index.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/index.shtml -
7/31/2019 Institute of Cancer
17/30
Section o Academic Radiotherapy & Department oRadiotherapy (including Psychology Research Group)Chairman: Proessor Alan Horwich
The main research theme o the Section o Radiotherapy is the development
and application o radiotherapy techniques, and there is extensive
collaboration with the Joint Physics Department. Current themes include:
applications o unctional imaging; assessment o image guidance,
such as with cone-beam Computed Tomography (CT) or Calypso seeds;
developments in delivery including Volumetric Modulated Arc Therapy
(VMAT) and Cyberknie.
New methods o external beam radiation require research relating to denition o target volumes,
quantication o benets rom rened treatment planning methods (including dose-volume toxicity
modelling), implementation and assessment o radiation beam delivery techniques, and careul quality
assurance to ensure the saety o new techniques in a clinical context. Alongside applications o physics
research, we investigate possible drug-radiation synergies. Our research aims to improve radiotherapy in
selected situations, to optimise techniques and to evaluate the benet o these approaches to the health
service.
Bladder Cancer/Testicular Cancer Dr Robert Huddart
Breast Cancer Proessor John Yarnold
Head & Neck Cancers Dr Christopher Nutting
Lung/CNS Tumours Proessor Michael Brada
Prostate Cancer Proessor David DearnaleyProstate Cancer Dr Christopher Parker
Psychology Research Group Dr Maggie Watson
Testicular Cancer/Lymphomas Proessor Alan Horwich
Section o Clinical TrialsChairman: Proessor Judith Bliss
The Clinical Trials and Statistics Unit (ICR-CTSU) was established in the 1980s
at the ICR as part o the Section o Epidemiology. In January 2004, the
ICR-CTSU was established as an independent research section (Section oClinical Trials) in recognition o its growth and National Cancer Research
Institute (NCRI) accreditation. The main objective o the ICR-CTSU is to design,
initiate, conduct and analyse national and international randomised clinical trials
o cancer treatment which will directly inuence routine clinical practice within
the National Health Serviceand worldwide.
Clinical Trials & Statistics Unit (ICR-CTSU) Proessor Judith Bliss
Deputy Director - Research Dr Emma Hall
Deputy Director - Operations Miss Claire Snowdon
POSTGRADUATE PROSPECTUS PAGE 17
http://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/bladder_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2948.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2944.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2950.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2954.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2955.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/teams/Psychology%20Research%20Group%20Home/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.nhs.uk/Pages/HomePage.aspxhttp://www.nhs.uk/Pages/HomePage.aspxhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.nhs.uk/Pages/HomePage.aspxhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/teams/Psychology%20Research%20Group%20Home/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2955.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2954.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2950.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2944.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2948.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/bladder_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtml -
7/31/2019 Institute of Cancer
18/30
-
7/31/2019 Institute of Cancer
19/30
Section o Haemato-oncologyChairman: Proessor Mel Greaves FRS
The Section o Haemato-oncology is an integrated Section that brings
together basic laboratory research, molecular diagnostics and treatment
o the blood cell cancers o adults and children (acute and chronicleukaemias, lymphomas and myeloma).
The Sections major objectives are:
To uncover the molecular mechanisms underlying the pathogenesis of
leukaemias, lymphomas and myeloma (i.e. the blood cell cancers)
To apply this knowledge to achieve two practical goals: (a) to advance our
understanding o the aetiology o leukaemia leading in the long term to the introduction o
preventive measures and (b) to improve the management o patients via the development o
new molecular tools or dierential diagnosis, prognosis, monitoring and treatment
Biology o Childhood Leukaemia Proessor Mel Greaves FRS
Leukaemia & Myeloma Molecular Genetics Proessor Gareth Morgan
Myeloma Targeted Treatment Dr Faith Davies
Stem Cells & Chromatin Dr Tomoyuki Sawado
Transcriptional Controls in Leukaemia Dr Arthur Zelent
The Section o Haemato-oncology is an integratedSection that brings together basic laboratory research,molecular diagnostics and treatment o the blood cellcancers o adults and children.
POSTGRADUATE PROSPECTUS PAGE 19
http://www.icr.ac.uk/research/research_sections/haemato_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/aetiology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/molecular_haematology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2885.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/myeloma_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2896.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/stem_cells_chromatin/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/9632.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/transcriptional_controls/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2892.shtmlhttp://www.icr.ac.uk/research/research_profiles/2892.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/transcriptional_controls/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/9632.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/stem_cells_chromatin/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2896.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/myeloma_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2885.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/molecular_haematology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/aetiology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/index.shtml -
7/31/2019 Institute of Cancer
20/30
Section o MedicineChairman: Proessor Stan Kaye
The Section o Medicine has the ollowing major spheres o activity:
Joint responsibility (with the Cancer Research UK Cancer TherapeuticsUnit) or the Drug Development Unit, based atThe Royal Marsden. The
clinical acility is housed in Oak Ward, and the total staf is more than 80.
The Unit sees upwards o 500 patients per year or new drug treatment,
and with around 30 open trials at any one time, it is one o the largest
such units in the world. Senior investigators are Proessor Stan Kaye,
Dr Johann de Bono, Dr Udai Banerjiand Dr Rhoda Molie
A laboratory programme focused on drug discovery and development in ovarian cancer. Proessor
Robert Brown(joint appointment with Imperial College) leads a team in conjunction with Proessor
Stan Kayeaiming to identiy new orms o epigenetic therapy in the context o drug resistant disease
A translational research programme, in conjunction with the Drug Development Unit, ocusing on
identiying cancer biomarkers in the context o new drug evaluation. This is led by Dr Johann de
Bono, who also has a specic interest in prostate cancer (utilising circulating tumour cells)
An integrative programme of core clinical fellows, linking the Section of Medicine to other ICR
Sections. These comprise clinical ellows in ovarian cancer drug development (supervised by
Proessor Stan Kaye, Dr Udai Banerji and Proessor Paul Workman o theCancer Research UK Cancer
Therapeutics Unit); and in prostate cancer (supervised by Dr Johann de Bonoand Proessor Colin
Cooperin the Prostate Collaborative)
Breast Cancer Proessor Ian Smith/
Proessor Stephen Johnston
Gastrointestinal Cancer Proessor David Cunningham
Lung Cancer Dr Mary OBrien
Sarcoma Proessor Ian Judson
Melanoma/Renal/Gynaecological Cancer Proessor Martin Gore
Prostate Cancer/Drug Evaluation Dr Johann de Bono
Gynaecological Cancer/Drug Evaluation Proessor Stan Kaye
Drug Evaluation Dr Udai Banerji
Epigenetics Proessor Robert Brown
/Dr Rhoda Molie
POSTGRADUATE PROSPECTUS PAGE 20
http://www.icr.ac.uk/research/research_sections/medicine/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www3.imperial.ac.uk/http://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/breast_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gastrointestinal_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/lung_cancer_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/sarcoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/skin_cancer_&_melanoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/epigenetics_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/epigenetics_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/skin_cancer_&_melanoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/sarcoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/lung_cancer_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gastrointestinal_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/breast_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www3.imperial.ac.uk/http://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/index.shtml -
7/31/2019 Institute of Cancer
21/30
Section o Molecular CarcinogenesisChairman: Proessor Colin CooperA major theme o the work o the Section is the application o the latest
molecular biological technologies to clinical problems identiied through
our links withThe Royal Marsden. Genomic inormation and newtechnologies generated rom the Cancer Genome Project have extended
the ocus to include research into identiying new prognostic and
diagnostic markers that may be o use in the management o sarcomas
and cancer o the prostate and testis. Agents potentially responsible or
many human cancers are still to be identiied, and a major objective o
Proessor David Phillips team is to identiy new classes o chemicals that may contribute to cancer
development. Dr Janet Shipleycollaborates closely with colleagues rom theSection o Paediatric
Oncologyto utilise ully the increasing amount o high quality genetic inormation that is becoming
available rom theHuman Genome Project.
Cell Transormation Proessor Colin Cooper
Human Biomonitoring & Carcinogen Activation Proessor David Phillips
Molecular Cytogenetics Dr Janet Shipley
A major theme o the work o the Section o MolecularCarcinogenesis is the application o the latest molecular
biological technologies to clinical problems identiedthrough our links with The Royal Marsden.
POSTGRADUATE PROSPECTUS PAGE 21
http://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.genome.gov/10001772http://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/cell_transformation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/human_biomonitoring_carcinogen_activation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/molecular_cytogenetics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/molecular_cytogenetics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/human_biomonitoring_carcinogen_activation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/cell_transformation/index.shtmlhttp://www.genome.gov/10001772http://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/index.shtml -
7/31/2019 Institute of Cancer
22/30
Our Campus
Chelsea SiteLondon has a packed programme o estivals andevents running throughout the year, together
with museums, art galleries and concert halls,
West End theatres and cinemas, restaurants,
pubs, clubs and bars, catering or all tastes. It
is the centre o politics and government with
many amous landmarks, including the Houses
o Parliament, St Pauls Cathedral, Buckingham
Palace, the Royal Albert Hall, the Tower o London
and Westminster Abbey. There are beautiul and
surprisingly large green spaces, such as Hyde
Park, Regents Park, Hampstead Heath and the
Botanical Gardens at Kew. The ICR is situated in
the heart o ashionable Chelsea with its designer
shops, bars and restaurants, only a stones throw
away rom the amous Kings Road and a short walk away rom the museums o South Kensington.
View a map and directions to the ICR at Chelsea
Sutton SiteOnly twelve miles rom central London, Sutton
is located in Surrey, close to the rolling NorthDowns. The historic towns o Guildord and
Kingston are nearby, and the south coast and the
popular resort o Brighton are only an hour away
by car. Sutton is a modern town with all the major
shops, together with restaurants, pubs, cinemas
and many amateur theatre and musical groups.
View a map and directions to the ICRat Sutton
POSTGRADUATE PROSPECTUS PAGE 22
http://www.icr.ac.uk/contact_us/chelsea/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/chelsea/index.shtml -
7/31/2019 Institute of Cancer
23/30
Student Support and Resources
Academic SupportThe ICR has well-dened procedures or monitoring research student progress and provides support
and training to students and supervisors. The Academic Dean and his panel o advisors vet all projects.
All projects, regardless o the source o unding, must be underwritten by the Section Chair (Head o
Department) to ensure continuity.
Only members o the ICRs rigorously selected aculty are permitted to supervise students. Faculty
members are highly experienced project and resource managers who, nevertheless, are required
to undergo ormal training in supervision beore they take on research students, and also attend
periodic update sessions. All students also have a back-up supervisor and, in some cases, an associate
supervisor as well; the supervisors are collectively reerred to as the supervisory team. Supervisors
submit reports on the work o their students to the Deans Team at least once a year, highlighting any
problem areas i appropriate.
In years 1-3 students have an annual review with the Deputy Dean or a Senior Tutor to review progress;
in the nal year they have three monthly meetings with the Deputy Dean/Senior Tutor. A major review
is undertaken ater the end o the rst year, when the decision to transer rom MPhil to PhD is made.
Students submit a comprehensive report o between 2,000 and 3,000 words, including a critique o
the work already carried out and a discussion o the uture development o the project, and are then
examined orally by the supervisory team and an independent (internal) assessor. At 30 months (2 years
and 6 months), students submit a shorter report, and in the third year they submit a thesis plan.
Students are required to keep a portolio, which is a comprehensive record o their learning and
achievement, including any ormal training undertaken during their programme o study at the ICR.The detail o portolio content is agreed between the student and the supervisory team and the
portolio is reviewed by a member o the Deans Team as part o the annual monitoring process.
All students are provided with their skeleton portolio in their rst term.
Submission rates and external examiner reports are monitored by the ICRs Academic Committees.
POSTGRADUATE PROSPECTUS PAGE 23
-
7/31/2019 Institute of Cancer
24/30
Resources or Research StudentsThe ICRs Interactive Education Unit (IEU) has developed two educational websites to provide background
knowledge and training or all research degree students. Study Skills provides tips on transerable skills
in areas relevant to completing a scientic research degree, while Perspectives in Oncology provides athorough and connected grounding in relevant aspects o cancer science and treatment. These resources
provide sel-directed learning in areas not covered by lectures, and are designed or researchers to
complete at a convenient time and location. They are also designed to accommodate diferent levels o
understanding in a subject matter.
Study Skills websiteThis provides advice and guidance on a range o transerable skills relevant to study
or a research degree, but can also be applied in uture employment both inside and outside o the
laboratory setting. Topics include scientic writing, time management and organisational skills, preparing
and presenting seminars, critical reading, and understanding intellectual property.
Perspectives in Oncology - the cancer science website This gives students rom all academic backgroundsan overview o the eld o cancer science and provides an insight into how the various disciplines
together help reveal the nature o cancer, the mechanisms underlying its development and spread, and
how it can be managed, treated and prevented. Current modules are: Cancer causes and prevention;
Tumour genetics; Common cancers; An approach to therapies; Bioinormatics; Medical physics; Basics o
tumour biology and Cell signalling. Additional modules currently being written are Structural biology and
Experimental therapeutics.
Find out more about The Interactive Education Unit
POSTGRADUATE PROSPECTUS PAGE 24
http://studyskills-ieu.icr.ac.uk/index.aspxhttp://studyskills-ieu.icr.ac.uk/index.aspxhttp://perspectives.icr.ac.uk/pages/5492_your-account.aspxhttp://www.icr.ac.uk/education/education_strategy/ieu/index.shtmlhttp://www.icr.ac.uk/education/education_strategy/ieu/index.shtmlhttp://perspectives.icr.ac.uk/pages/5492_your-account.aspxhttp://studyskills-ieu.icr.ac.uk/index.aspx -
7/31/2019 Institute of Cancer
25/30
Library and Inormation ServicesThe ICR has libraries on both sites, with 24-hour access available or registered users. Qualiied
library sta are available to help with any enquiries.
We have 5,000 electronic journal subscriptions, covering a number o specialist scientiic and
clinical ields, including biochemistry, chemistry, cell biology, genetics, pharmacology, oncology,
medical physics, immunology, surgery and anaesthetics. These can be accessed in the library, on
desktops throughout the ICR, or elsewhere. Where possible, physical copies o these journals are
also available, and the library has access to a growing number o electronic archives.
There are 5,000 books held between the two libraries -- covering all o the scientiic and clinical
research areas o interest -- and the library catalogue is available on the Internet. Online databases
and resources currently available or use both in the library and o-site include PubMed, Cochrane
Library, Faculty o 1000 Biology, Reaxys, Web o Knowledge and Zetoc. A series o online scientiic
lectures (the Henry Stewart Talks) is also available.
The libraries in both Chelsea and Sutton provide pleasant areas with numerous spaces or users to
browse the collections. In both libraries there are dedicated PhD study rooms, with PCs and printing
acilities available or readers, as well as plug sockets, network ports and wireless access or laptop
use.
Find out more about Library and Inormation Services
POSTGRADUATE PROSPECTUS PAGE 25
http://www.icr.ac.uk/education/education_strategy/icr_library/index.shtmlhttp://www.icr.ac.uk/education/education_strategy/icr_library/index.shtml -
7/31/2019 Institute of Cancer
26/30
The RegistryThe Registry has responsibility or student-related administration, including:
Studentships
Recruitment and admissions Enrolment
Student records
Statutory reporting of student data
Student examinations and assessments/external examining
Degree Ceremony organisation
Developing higher education (HE) quality assurance and quality enhancement procedures
Servicing a number of academic and non-academic related committees
Servicing the Academic Deans meetings and business of the Academic Deans Team
Handling student cases Arranging conferences and lectures
Liaison with HE government agencies, the Quality Assurance Agency (QAA) and the University
o London
Involvement in taught course support, administration, teaching and learning
Registry sta are available to assist with queries or problems that may arise during your programme
o study
Learning and Development
The Learning and Development team provides a wide range o activities to support the personal andproessional development o students. These are based on the recommendations o the Research Councils
as to the key skills needed to build a successul research career - research skills and techniques, knowledge
o the research environment, research management, personal efectiveness, communication skills, team-
working, networking skills and career management.
We aim to provide all researchers with 10 days personal development per annum consisting o classroom
training courses, online learning, seminars on cutting-edge scientic techniques and work-based coaching.
We also provide internal and external careers advice and inormation to students.
POSTGRADUATE PROSPECTUS PAGE 26
-
7/31/2019 Institute of Cancer
27/30
Our Commitment to Equality and DiversityThe ICR promotes equality o opportunity in employment and teaching and opposes all orms o unlawul
discrimination on the grounds o any o the characteristics protected by law (race, sex, age religion or
belie, sexual orientation, disability, marriage or civil partnership, pregnancy and maternity, genderreassignment). The ICR also recognises that discrimination can arise rom other social actors, such as
caring responsibilities and personal background, and we are committed to creating an environment
where each individuals participation and advancement is based purely on merit.
The ICR will not tolerate discrimination by any o its staf or students. Unlawul discrimination and
harassment are regarded as gross misconduct and will be treated as a serious disciplinary matter.
Support or Disabled StudentsThe ICR aims to meet the needs o all students and considers each individual on academic merit. The
ICR has successully supported students with a range o disabilities and we take care to ensure that
inormation, advice and a support service are available to students who have welare or disability issues.The ICR has a student guide to disability services that outlines the support we ofer to students.
I you have any questions relating to your disability and studying at the ICR, you can contact the
Academic Registry at any stage in your application or advice and urther inormation.
The ICR aims to meet the needs o all students andconsiders each individual on academic merit.
POSTGRADUATE PROSPECTUS PAGE 27
-
7/31/2019 Institute of Cancer
28/30
CondentialityUnder the Data Protection Act 1998, any
inormation you disclose regarding your
disability and/or additional needs will be dealtwith in the strictest condence and inormation
about your disability will not be passed on
without your specic consent. Please bear in
mind that without knowledge o your disability,
it may be dicult to ully support your needs
and make the necessary adjustments. As
the ICR is predominantly a laboratory-based
environment, it is important that students who
work in a laboratory inorm their tutors o any
relevant medical condition or health and saety
purposes.
Data ProtectionThe ICR is committed to responsible data
processing in accordance with its legal
obligations as a data controller under The Data
Protection Act 1998 (the Act) and associated
codes o practice issued by the Inormation
Commissioner. Our policy aims to ensure that
all individuals about whom the ICR processes
data are properly inormed about the eect
o the Act in respect o both their rights and
their obligations.
POSTGRADUATE PROSPECTUS PAGE 28
-
7/31/2019 Institute of Cancer
29/30
How to ApplyEligibility Criteria
Each academic year, the ICR invites applications or 15-20 our-year ull-time PhD studentships.In order to apply, students must meet the ollowing criteria:
Hold a rst or upper second class honours degree in a relevant subject (either expected or obtained)
rom a UK University OR hold an overseas qualication to the equivalent level
Have experience of laboratory or research work; one of your referees must be able to comment on
your research experience
Have a TOEFL score of 650 (paper-based), 280 (computer-based) or 114 (Internet-based) OR an IELTS
score o at least 7. Students without TOEFL or IETLS score should have either education experience in
English (min. 1 year) or work experience (min. 18 months)
Application GuidelinesAll applications must be made via the online orm.
A completed application consists o:
An online application form, where you have uploaded a summary of a research project and your
degree transcript i you are rom overseas.
Details of two references (one of whom must be able to comment on your research abilities)
Your referees will be contacted immediately. They will be emailed a link to a form which they
complete. You will receive an email when they have done this. I you do not receive this email, you
should contact your reerees: it is your responsibility to ensure that we receive your reerences
The deadline or applications is Wednesday 1st December 2010.I your application is successul you will be notied the week commencing Monday 20th December 2010
Interviews will be held rom Sunday 30th January Tuesday 1st February 2011.
LinksHow to Apply|The ICR Admission Policy| What to Expect at Interview
POSTGRADUATE PROSPECTUS PAGE 29
http://www.icr.ac.uk/education/science_students_opportunities/studentships/index.shtmlhttp://www.icr.ac.uk/education/science_students_opportunities/studentships/index.shtmlhttp://www.icr.ac.uk/education/science_students_opportunities/studentships/available_studentshi